BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Le Berre C, Peyrin-Biroulet L; SPIRIT-IOIBD study group. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology 2021;160:1452-1460.e21. [PMID: 33421515 DOI: 10.1053/j.gastro.2020.10.065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond) 2021;21:135-9. [PMID: 33762374 DOI: 10.7861/clinmed.2021-0080] [Reference Citation Analysis]
2 le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022:S0016-5085(21)04067-1. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zilbauer M, Heuschkel R. Disease Prognostic Biomarkers in Inflammatory Bowel Diseases—A Reality Check. Journal of Crohn's and Colitis 2021. [DOI: 10.1093/ecco-jcc/jjab118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Spencer EA, Dubinsky MC. Precision Medicine in Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am 2021;68:1171-90. [PMID: 34736583 DOI: 10.1016/j.pcl.2021.07.011] [Reference Citation Analysis]
5 Alsoud D, Vermeire S, Verstockt B. Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100089] [Reference Citation Analysis]
6 Kayal M, Ungaro RC, Riggs A, Kamal K, Agrawal M, Cohen-Mekelburg S, Axelrad J, Faye A, Scherl E, Lawlor G, Sultan K, Lukin D, Dubinsky MC, Colombel JF; New York Crohn’s and Colitis Organization (NYCCO). Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00571-1. [PMID: 34033922 DOI: 10.1016/j.cgh.2021.05.033] [Reference Citation Analysis]
7 Pariente B, Torres J, Burisch J, Arebi N, Barberio B, Duricova D, Ellul P, Goldis A, Kaimakliotis I, Katsanos K, Krznaric Ž, McNamara D, Pedersen N, Sebastian S, Azahaf M, Weimers P, Lung P, Lacognata C, Horak M, Christodoulou D, Domislovic V, Murphy I, Lambert J, Ungaro R, Colombel JF, Mary JY. Validation and Update of the Lémann Index to Measure Cumulative Structural Bowel Damage in Crohn's Disease. Gastroenterology 2021;161:853-864.e13. [PMID: 34052277 DOI: 10.1053/j.gastro.2021.05.049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sparrow MP. Quantification of Digestive Disease Damage in Crohn's Disease, Are We There Yet With the Lémann Index? Gastroenterology 2021;161:800-2. [PMID: 34175282 DOI: 10.1053/j.gastro.2021.06.047] [Reference Citation Analysis]
9 Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis 2021:izab228. [PMID: 34480558 DOI: 10.1093/ibd/izab228] [Reference Citation Analysis]
10 Guo X, Huang C, Xu J, Xu H, Liu L, Zhao H, Wang J, Huang W, Peng W, Chen Y, Nie Y, Zhou Y, Zhou Y. Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. Front Nutr 2022;8:818902. [DOI: 10.3389/fnut.2021.818902] [Reference Citation Analysis]
11 Laharie D, D'Haens G, Nachury M, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, Janneke van der Woude C, Buisson A, Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, Picon L, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L. Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01268-4. [PMID: 34843987 DOI: 10.1016/j.cgh.2021.11.030] [Reference Citation Analysis]
12 Verstockt B, Parkes M, Lee J. How Do We Predict a Patient's Disease Course and Whether They Will Respond to Specific Treatments? Gastroenterology 2022:S0016-5085(21)04081-6. [PMID: 34995535 DOI: 10.1053/j.gastro.2021.12.245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 Lommatzsch M, Brusselle GG, Canonica GW, Jackson DJ, Nair P, Buhl R, Virchow JC. Disease-modifying anti-asthmatic drugs. The Lancet 2022;399:1664-8. [DOI: 10.1016/s0140-6736(22)00331-2] [Reference Citation Analysis]
14 Torres J, Ungaro RC, Colombel JF. Is Prevention the Best Way to Modify Inflammatory Bowel Disease? How Close Are We? Gastroenterology 2022;162:1452-5. [PMID: 34995527 DOI: 10.1053/j.gastro.2021.07.051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Noor NM, Parkes M, Raine T. Moving towards more patient-centred clinical trials in IBD. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34312526 DOI: 10.1038/s41575-021-00500-x] [Reference Citation Analysis]